Endogenous fibrinolytic system (Fibrinolytic System)

The endogenous fibrinolytic system is a highly regulated biological pathway responsible for the degradation of fibrin clots to maintain vascular patency. Its primary components include plasminogen, which binds to fibrin and is converted to the active enzyme plasmin by tissue-type plasminogen activator (tPA) or urokinase-type plasminogen activator (uPA). This system is critically influenced by the presence of thrombin, which not only forms the clot but also activates Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) to protect the clot from premature degradation. When systemic thrombin inhibition occurs (e.g., via anticoagulants), the activation of TAFI is suppressed, leading to an enhanced rate of fibrinolysis at the fibrin-plasminogen interface. Understanding this interplay is vital for managing thrombotic disorders and optimizing thrombolytic therapies, as it highlights how anticoagulation can synergistically promote the body's natural ability to dissolve clots.

Other names

Plasminogen-plasmin systemFibrinolytic pathwayThrombolytic system

The system functions through the conversion of the zymogen plasminogen into the active serine protease plasmin by activators like tPA or uPA. Plasmin then enzymatically degrades the fibrin matrix of blood clots. Systemic thrombin inhibition enhances this process by preventing the activation of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI), which normally removes C-terminal lysine residues from fibrin that are essential for plasminogen binding.